ArticleCureus2025
Rivaroxaban Treatment in Pediatric Patients With Hematologic Malignancies and Venous Thromboembolism: A Report of Four Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism is a serious complication in pediatric patients with hematologic malignancies, with acute pulmonary thromboembolism (PTE) posing a significant risk of cardiopulmonary collapse. Since the pediatric approval of rivaroxaban in 2021, marking the introduction of direct oral anticoagulants (DOACs) for this population, we have encountered four cases of thrombosis in children with hematologic malignancies. These included a six-year-old boy with B-cell precursor acute lymphoblastic leukemia treated with heparin followed by rivaroxaban for PTE; a 14-year-old girl with T-lymphoblastic lymphoma (T-LBL) who developed recurrent jugular vein thrombosis and discontinued rivaroxaban due to bleeding; a 10-year-old boy with T-LBL who survived life-threatening PTE with heparin and subsequent rivaroxaban therapy; and a 15-year-old girl with Hodgkin lymphoma who was managed with heparin and rivaroxaban for jugular vein thrombosis. All patients initially received heparin, followed by rivaroxaban for maintenance anticoagulation. Follow-up imaging confirmed thrombus resolution and no recurrence in all cases. Rivaroxaban proved effective in treating venous thrombosis in these pediatric patients, with successful outcomes and an overall favorable safety profile, underscoring the emerging role of DOACs in pediatric thrombosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.